These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. PET response assessment in apatinib-treated radioactive iodine-refractory thyroid cancer. Wang C; Zhang X; Yang X; Li H; Cui R; Guan W; Li X; Zhu Z; Lin Y Endocr Relat Cancer; 2018 Jun; 25(6):653-663. PubMed ID: 29618578 [TBL] [Abstract][Full Text] [Related]
31. Imaging with (124)I in differentiated thyroid carcinoma: is PET/MRI superior to PET/CT? Binse I; Poeppel TD; Ruhlmann M; Gomez B; Umutlu L; Bockisch A; Rosenbaum-Krumme SJ Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1011-7. PubMed ID: 26686334 [TBL] [Abstract][Full Text] [Related]
33. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. Kolbert KS; Pentlow KS; Pearson JR; Sheikh A; Finn RD; Humm JL; Larson SM J Nucl Med; 2007 Jan; 48(1):143-9. PubMed ID: 17204711 [TBL] [Abstract][Full Text] [Related]
34. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Chiesa C; Mira M; Maccauro M; Spreafico C; Romito R; Morosi C; Camerini T; Carrara M; Pellizzari S; Negri A; Aliberti G; Sposito C; Bhoori S; Facciorusso A; Civelli E; Lanocita R; Padovano B; Migliorisi M; De Nile MC; Seregni E; Marchianò A; Crippa F; Mazzaferro V Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1718-1738. PubMed ID: 26112387 [TBL] [Abstract][Full Text] [Related]
35. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Chiesa C; Castellani MR; Vellani C; Orunesu E; Negri A; Azzeroni R; Botta F; Maccauro M; Aliberti G; Seregni E; Lassmann M; Bombardieri E Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):546-61. PubMed ID: 19910908 [TBL] [Abstract][Full Text] [Related]
36. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. de Keizer B; Brans B; Hoekstra A; Zelissen PM; Koppeschaar HP; Lips CJ; van Rijk PP; Dierckx RA; de Klerk JM Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):367-73. PubMed ID: 12634964 [TBL] [Abstract][Full Text] [Related]
37. Advantages of dosimetry in 131I therapy of differentiated thyroid carcinoma. Verburg FA Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):253-257. PubMed ID: 31271272 [TBL] [Abstract][Full Text] [Related]